Who is Bryan Johnson: Anti-aging champion who spent $2 million a year on his body now set to shut down or sell age-reversing startup due to financial losses
, the tech entrepreneur turned
longevity
icon, is preparing to shut down his
age-reversal startup
, Blueprint, due to ongoing financial losses and his shifting philosophical priorities. The supplement-selling startup, which was born from his intense personal health experiment, aimed to commercialize parts of his $2 million-a-year
anti-aging
regimen. Despite attracting widespread media attention and a dedicated wellness following, Johnson says the business has become a distraction from his deeper mission to 'defy death.' Known for his strict diet protocols, hundreds of medical tests, and even plasma transfusions from his teenage son, Johnson is now walking away from
Blueprint
to focus fully on his emerging philosophical movement, 'Don't Die.'
Bryan Johnson's evolution from tech tycoon to immortality evangelist
Born on August 22, 1977, in Provo, Utah, and raised in nearby Springville, he grew up on a farm, helping with alfalfa and corn alongside his four siblings. After his parents divorced, he lived with his mother and stepfather. At 19, he spent two years as a missionary in Ecuador with the Church of Jesus Christ of Latter-day Saints. Returning to the United States, he earned a BA in International Studies from Brigham Young University in 2003 and later completed his MBA at the University of Chicago Booth School of Business in 2007.
His breakthrough came in 2007 when he founded Braintree, a mobile and web payment processing company. Bootstrapped and focused, it served clients like Airbnb, Uber, and GitHub before acquiring Venmo in 2012. The company was sold to PayPal for $800 million in 2013, netting Johnson around $300 million.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
This Could Be the Best Time to Trade Gold in 5 Years
IC Markets
Learn More
Undo
After the sale of Braintree, he redirected his wealth into ambitious scientific ventures. He launched OS Fund with $100 million to support frontier science and, in 2016, founded Kernel, a company aimed at developing brain-monitoring neurotechnology—specifically, helmet devices capable of creating real-time models of brain activity.
However, it was his personal immersion in
Project Blueprint
, a daily regimen costing more than $2 million annually, that elevated him from entrepreneur to anti-aging evangelist.
In March 2025, Johnson introduced the 'Don't Die' movement, positioning it as a philosophical or even religious shift and asserting that existence is humanity's highest virtue. He now sees commercial ventures like Blueprint as distractions from this mission and believes that selling products undermines his credibility as a messenger of the cause.
Project Blueprint: The $2 million-a-year body experiment
Johnson's Blueprint regimen includes a vegan diet, more than 100 daily pills, exercise, sleep optimization, and near-daily tests tracking everything from liver fat to brain function. He claims to have slowed his epigenetic aging, achieving the biological metrics of an 18-year-old while in his 40s. While critics question the reproducibility and ethics of such intense interventions, Johnson has branded himself as a 'professional rejuvenation athlete,' turning his body into a living experiment in age reversal.
Why he's walking away from Blueprint
In his own words, Johnson described Blueprint the company as a 'pain-in-the-a**' venture. He no longer wants to trade his philosophical credibility for profit and admits that continuing to run a commercial enterprise distracts from his mission to reshape humanity's relationship with death. While some speculate that Blueprint's financial viability was a key reason behind his decision, Johnson emphasizes that the shift is ideological. He insists that his full attention must now be devoted to Don't Die, which he views as a new kind of spiritual framework for the age of artificial intelligence and life extension.
What's next for Bryan Johnson
Johnson says he is close to making a final decision to either sell or shut down Blueprint entirely. Moving forward, his focus will be on expanding Don't Die into a comprehensive movement—a religion, a philosophy, and potentially a post-capitalist vision for human existence. Whether seen as a visionary or an eccentric billionaire with a messiah complex, Bryan Johnson has placed himself at the center of one of the most radical and intriguing quests of our time: to stop dying altogether.
AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
8 minutes ago
- Time of India
Adani Power Q1 results: Net profit falls 16% to Rs 3,305 crore; revenue declines on lower tariffs and higher costs
Adani Power Ltd (APL) reported a 15.53% decline in consolidated net profit for the April-June quarter, with earnings falling to Rs 3,305 crore amid pressure from subdued merchant tariffs and elevated operating costs linked to recent acquisitions. The country's largest private thermal power producer had posted a net profit of Rs 3,913 crore in the same period last year. Despite the year-on-year drop, net profit rose 27.1% sequentially, aided by one-time income and continued EBITDA momentum, PTI reported. Revenue from operations declined to Rs 14,167 crore in Q1 FY26, compared to Rs 15,052 crore in the year-ago quarter, mainly due to lower realisation from merchant sales and falling import coal prices. EBITDA for the quarter stood at Rs 5,744 crore, down from Rs 6,290 crore a year earlier. The company said while a moderation in fuel costs provided some relief, operating expenses increased following the acquisition of multiple assets. APL's installed capacity rose to 17,550 MW during the quarter, from 15,250 MW earlier, after acquiring the 1,200 MW Moxie Power Generation Ltd, 600 MW Korba Power Ltd, and 500 MW Adani Dahanu Thermal Power Station. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Flexible in AI & Data Science BITS Pilani Digital Apply Now With the completion of the 600 MW Vidarbha Industries Power Ltd deal in July, total capacity reached 18,150 MW. The company achieved a plant load factor (PLF) of 67% in Q1. Total power sales rose 1.6% year-on-year, driven by the increase in operational capacity and higher offtake from select plants. Merchant sales for the quarter were up 7.7% at 5.7 billion units, compared to 5.3 BU in Q1 FY25. The Godda plant in Jharkhand, which supplies power to Bangladesh, has started receiving regular payments from the Bangladesh Power Development Board, with inflows of $437 million in June and another $75 million in July 2025. 'Stable financial performance this quarter is a testament to its resilience and core strengths, even in the face of variability in power demand and unpredictable weather,' said S B Khyalia, CEO of Adani Power. 'We continue to bolster our capacity through swift project execution and strategic acquisitions, ensuring we are well-prepared for future growth on our path to 30 Giga Watts (GW) by 2030.' Total debt stood at Rs 44,372 crore as of June 30, 2025, compared to Rs 38,335 crore at the end of March. Net debt rose to Rs 37,437 crore from Rs 31,023 crore in the same period. The company said the increase was due to bridge loans for capex and higher working capital needs in line with expanding operations. Adani Power currently operates 18,110 MW of thermal capacity across 12 locations in Gujarat, Maharashtra, Karnataka, Rajasthan, Chhattisgarh, Madhya Pradesh, Jharkhand, and Tamil Nadu, in addition to a 40 MW solar power plant in Gujarat. Stay informed with the latest business news, updates on bank holidays and public holidays . Discover stories of India's leading eco-innovators at Ecopreneur Honours 2025
Time of India
14 minutes ago
- Time of India
China accuses US of 'using' Microsoft 'bug' to spy on Chinese Military
Microsoft is again caught in China vs US cyber battle. This time China has accused America of using Microsoft bug to spy on the Chinese Military. According to a report in Bloomberg, China has accused the US of exploiting a flaw in Microsoft Corp's email servers to steal military data and launch cyberattacks on its defense sector. The accusations come from the Cyber Security Association of China. The association is backed by the powerful Cyberspace Administration of China. In a statement, the Cyber Security Association of China said that US actors had been linked to two major cyberattacks on Chinese military companies without naming them. They exploited flaws in Microsoft Exchange to control the servers of a key company in the defense sector for nearly a year, it added. Microsoft has repeatedly blamed China for major cyberattacks involving Microsoft Exchange. In 2021, an alleged Chinese operation compromised tens of thousands of Microsoft Exchange servers. In 2023, another alleged Chinese attack on Microsoft Exchange compromised senior US government officials' email accounts. Microsoft accuses Chinese hackers of exploiting SharePoint software by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like We Have No Words For Dog The Bounty Hunter's Transformation. Cash Roadster More recently, Microsoft said Chinese state-backed hacking groups had exploited vulnerabilities in its SharePoint file sharing software. Microsoft SharePoint is widely regarded as one of the biggest security breaches ever that impacted organisations world wide, including several US government departments. Chinese "threat actors" have hacked some Microsoft SharePoint servers and targeted the data of the businesses using them, the company said. According to reports, hackers breached about 400 government agencies, corporations and other groups around the world. According to cybersecurity researchers, most of the victims are in the US, followed by Mauritius, Jordan, South Africa and the Netherlands. Microsoft released security updates in response and advised all on-premises SharePoint server customers to install them. In response to Microsoft's claims, China's US embassy spokesman said in a statement, "China firmly opposes and combats all forms of cyber attacks and cyber crime." AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
19 minutes ago
- Time of India
70% enrolment of participants for Phase III clinical trial of dengue vaccine completed: Centre
Seventy percent enrolment of participants for the Phase III clinical trial of the indigenous one-shot dengue vaccine , DengiAll , has been completed, Minister of State for Health, Prataprao Jadhav, told Lok Sabha on Friday. The Indian Council of Medical Research ( ICMR ) has undertaken a clinical trial titled phase III, multicentre, randomised, double-blind, placebo controlled study to evaluate the efficacy, immunogenicity and safety of the single-dose Dengue Tetravalent vaccine, live attenuated (Recombinant, Lyophilised) - 'DengiAll', Jadhav said in a written reply. Explore courses from Top Institutes in Please select course: Select a Course Category Cybersecurity Project Management MCA Finance MBA PGDM Technology Healthcare Data Science Data Analytics CXO Design Thinking Data Science Leadership others healthcare Degree Others Digital Marketing Management Artificial Intelligence Product Management Public Policy Operations Management Skills you'll gain: Duration: 10 Months MIT xPRO CERT-MIT xPRO PGC in Cybersecurity Starts on undefined Get Details "The trial involves over 10,000 participants, out of which more than 70 per cent enrolment has been completed. The trial has been implemented in 20 sites across India," he said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like War Thunder - Register now for free and play against over 75 Million real Players War Thunder Play Now Undo The sites are JSS Medical College and Hospital, Mysuru (Karnataka), Bangalore Medical College and Research Institute, and All India Institute of Medical Sciences, Bibinagar (Telangana). The approximate budget for the trial is Rs 1.3 to 1.5 crore per site, Jadhav said. Live Events According to ICMR, there is no specific antiviral treatment or licensed vaccines for dengue and the treatment is supportive in nature, Jadhav said. A total of 5,73,563 laboratory confirmed dengue cases were reported through the Integrated Health Information Platform (IHIP) in 2024, according to information shared by the National Centre for Disease Control (NCDC) , . According to ICMR, all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV -4) are known to circulate and co-circulate in India. Multiple serotypes can be present in the same geographical region and can even infect the same individual at the same time. Hence, participants have been enrolled in the ICMR vaccine trial from different zones where these four serotypes circulate in order to test the efficacy of the vaccine against all four serotypes, Jadhav said. The minister also said that the Union Health Ministry, Director General of Health Services, and National Centre for Vector Borne Disease Control (NCVBDC) regularly monitor the situation of dengue outbreaks across the country for assessing the disease situation, preparedness, technical guidance and to sensitise and forewarn the states. Under the National Health Mission, adequate budgetary support is provided to states and Union territories for dengue control activities such as epidemic preparedness, monitoring, case management, vector control (provision of domestic breeding checkers, ASHA involvement, insecticide, fogging machines), training, intersectoral convergence, awareness activities, etc. For surveillance and free of cost diagnosis of dengue, Sentinel Surveillance Hospitals with laboratory facility and Apex Referral laboratories with advance diagnostic facilities have been identified across the country, Jadhav said. The government of India has developed national guidelines on dengue treatment/management, in consultation with experts, which have been shared with all the states and UTs for implementation. The guidelines emphasise the preparedness of hospitals for case treatment/management. In addition, advisories have been issued from time to time to states/UTs for prevention and control of dengue, including case management, the minister said.
